Home/Filings/4/0001493152-21-015024
4//SEC Filing

Bailey Webster 4

Accession 0001493152-21-015024

CIK 0000315545other

Filed

Jun 21, 8:00 PM ET

Accepted

Jun 22, 5:25 PM ET

Size

11.3 KB

Accession

0001493152-21-015024

Insider Transaction Report

Form 4
Period: 2021-06-17
Transactions
  • Award

    8% Secured Convertible Promissory Notes due 2021

    2021-06-17
    Exercise: $2.86From: 2021-06-17Exp: 2021-06-20Series D-1 Convertible Preferred Stok (41,323 underlying)
  • Exercise/Conversion

    Series D-1 Convertible Preferred Stock

    2021-06-20+41,32341,323 total
    From: 2021-06-20Common Stock (413,230 underlying)
  • Exercise/Conversion

    8% Secured Convertible Promissory Notes due 2021

    2021-06-200 total
    Exercise: $2.86From: 2021-06-17Exp: 2021-06-20Series D-1 Convertible Preferred Stock (41,323 underlying)
Footnotes (4)
  • [F1]The Issuer issued the 8% secured convertible promissory notes due 2021 to the Reporting Person on March 11, 2019, which were amended on May 14, 2019 (the "Notes"). At the time of issuance, the Issuer had not filed a Certificate of Designation for the Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Convertible Preferred Stock") and, therefore, there was no security underlying the Notes into which the Notes could convert. On June 17, 2021, the Issuer filed a Certificate of Designation with the Delaware Secretary of State to create the Series D-1 Convertible Preferred Stock and, upon the filing of the Certificate of Designation, the Notes became a derivative security.
  • [F2]On June 20, 2021, the Notes automatically converted into Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the Notes.
  • [F3]Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
  • [F4]The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Documents

1 file

Issuer

PROVECTUS BIOPHARMACEUTICALS, INC.

CIK 0000315545

Entity typeother

Related Parties

1
  • filerCIK 0001818267

Filing Metadata

Form type
4
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 5:25 PM ET
Size
11.3 KB